Abiraterone Acetate Drugs Market Size - Global Industry, Share, Analysis, Trends and Forecast 2024 - 2032

Abiraterone Acetate Drugs Market Highlights

• Global abiraterone acetate drugs market revenue is poised to garner USD 5.1 billion by 2032 with a CAGR of 7.9% from 2024 to 2032
• North America abiraterone acetate drugs market value occupied around USD 988 million in 2023
• Asia-Pacific abiraterone acetate drugs market growth will record a CAGR of more than 8.6% from 2024 to 2032
• Combining abiraterone acetate with other treatments, such as chemotherapy or androgen deprivation therapy (ADT) is the abiraterone acetate drugs market trend that fuels the industry demand

Abiraterone acetate is often referred to as Zytiga. An oral drug used largely to treat prostate cancer, namely metastatic castration-resistant prostate cancer (mCRPC). It acts by blocking CYP17A1, an enzyme that produces androgens (male hormones). By reducing androgen levels, it slows cancer cell proliferation. It is typically used with prednisone to treat hormone-related adverse effects. Abiraterone acetate is often used when other prostate cancer treatments have failed, extending survival and improving quality of life. It is typically used in conjunction with other therapies, such as chemotherapy or radiation therapy, depending on the patient's condition.

Global Abiraterone Acetate Drugs Market Dynamics

Market Drivers

• Rising prevalence of prostate cancer globally
• Increasing adoption of targeted therapy in oncology
• Expansion of healthcare infrastructure in emerging economies

Market Restraints

• High cost of branded abiraterone acetate drugs
• Stringent regulatory requirements for drug approval
• Side effects and contraindications limiting usage in specific populations

Market Opportunities

• Growth of generic drug production and affordability
• Expanding applications in off-label cancer treatments
• Rising demand for online pharmacies and direct-to-consumer sales channels

Abiraterone Acetate Drugs Market Report Coverage

Abiraterone Acetate Drugs Market Insights

The growing number of hospital patients diagnosed with prostate cancer, together with quick improvements in the medical industry to deliver innovative remedies, is significant drivers of the global abiraterone acetate pharmaceuticals market. For example, the American Cancer Society (ACS) predicts that in 2024, there will be 299,010 new instances of prostate cancer, accounting for 14.9% of all cancer diagnoses. Additionally, an estimated 35,250 deaths are projected, accounting for 5.8% of all cancer-related mortality. Furthermore, bad living habits and increased consumption of junk food are having a negative impact on health results. The Breast Cancer Organization estimates that dietary variables impact 30% to 40% of all cancer cases. Furthermore, the National Institute of Health states that, high consumption of ultra-processed food (UPF) is associated with an increased risk of acquiring colorectal and pancreatic cancer.

Leading businesses are making major expenditures in sophisticated solutions, including continued attempts to expand clinical studies and develop new medications, which are projected to drive market growth. Enterprises' aggressive attitude to expanding their presence in developing nations, combined with favorable business policies, is expected to attract important players and boost the growth of the abiraterone acetate pharmaceuticals market. However, constraints such as expensive medication development costs and tight government regulations for product approval are projected to impede market expansion.

Furthermore, the lack of competent R&D infrastructure in emerging countries limits market expansion. On the other hand, large firms' increased investments in the healthcare industry, significant government spending on healthcare infrastructure development, and an increase in the number of clinical trials are likely to open up new growth potential. According to the India Brand Equity Foundation (IBEF), the Indian healthcare sector is seeing unprecedented growth, with private equity and venture capital investments exceeding US$ 1 billion in the first five months of 2024, representing a 220% increase over the previous year. Furthermore, strategic collaborations between leading firms to strengthen distribution channels are likely to increase revenue creation in the market throughout the forecast period.

Abiraterone Acetate Drugs Market Segmentation

The worldwide market for abiraterone acetate drugs is split based on test, strength, product type, distribution channel, and geography.

Abiraterone Acetate Market By Dosage Form

• Film-Coated Tablet
• Uncoated Tablet

According to the abiraterone acetate drugs industry analysis, the film-coated tablet is gaining popularity due to its advantages in ease of swallowing, controlled medication release, and preservation of the active ingredient from environmental influences. The film covering also improves patient compliance and provides a more pleasant experience than uncoated pills. Uncoated tablets, while still used, are less popular due to their more basic formulation and lack of degradation resistance. They do, however, provide a more affordable option for patients.

Abiraterone Acetate Drugs Market By Strength

• 125 mg
• 250 mg
• 500 mg

According to the abiraterone acetate drugs industry analysis, the 250 mg strength is expected to lead because it is the most typically given dosage for treating prostate cancer, which aligns with established treatment practices. Its extensive availability and proven performance make it the favored choice for both healthcare practitioners and patients. The 125 mg and 500 mg strengths meet particular dosage requirements, providing flexibility for tailored treatment strategies. These variances are necessary for adapting therapy to individual patient demands, which contributes to market growth.

Abiraterone Acetate Drugs Market By Product Type

• Generic
• Branded

According to the abiraterone acetate drugs industry analysis, branded product market is rapidly expanding, owing to strong trust and demand for established pharmaceutical brands among healthcare providers and patients. Branded pharmaceuticals frequently benefit from substantial clinical research, proven efficacy, and effective marketing efforts, making them a preferred choice despite their greater cost. Branded pharmaceuticals are projected to continue to expand significantly as formulations improve and new therapies are introduced.

Abiraterone Acetate Drugs Market By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

According to the abiraterone acetate drugs market forecast, hospital pharmacies dominate because they play an important role in distributing specialty oncology medications directly to patients under physician supervision. They are the preferred distribution route for cancer therapies because they provide educated personnel and immediate access to prescription drugs. Retail and internet pharmacies are both expanding steadily, with retail pharmacies catering to patient convenience and online platforms providing quick access and competitive pricing, particularly in developed regions.

Abiraterone Acetate Drugs Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of LATAM

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Abiraterone Acetate Drugs Market Regional Analysis

For several reasons, the North American market is expected to account for a large portion of revenue in the global abiraterone acetate pharmaceuticals market, owing to the region's high cancer prevalence. For example, the National Cancer Institute estimates that in 2024, 2,001,140 new instances of cancer will be identified in the United States, with 611,720 individuals dying from the disease. Prostate, lung, and colorectal cancers will account for an estimated 48% of all malignancies diagnosed in males by 2024. Breast, lung, and colorectal cancers are the three most frequent among women, accounting for an anticipated 51% of all new cancer diagnoses in 2024. Advanced R&D infrastructure, increased clinical trial activity, and expanding public investments by public entities are key factors fueling market growth. Additionally, the large number of industry players and the continuous introduction of new products further support the market's expansion in this region.

The market in Asia-Pacific is likely to grow at a quicker rate as governments invest more in the healthcare sector. Governments are undertaking a variety of health initiatives to boost patient awareness and encourage the use of improved therapies. For example, in 2023, the Indian government, primarily through the Department of Pharmaceuticals, is actively promoting new drug development through initiatives like the "Scheme for Promotion of Research & Innovation in Pharma Sector (PRIP)" which aims to transform the Indian pharmaceutical sector from cost-based to innovation-based by funding research and development projects, with the goal of creating new drugs and medical technologies. The Central pharmaceuticals Standard Control Organization (CDSCO) is India's regulatory organization in charge of licensing new pharmaceuticals. Evolving medical legislation, as well as the expansion of hospital infrastructure aimed at providing better care, is expected to have a beneficial impact on the growth of the target market in this region.

Abiraterone Acetate Drugs Market Players

Some of the top abiraterone acetate drugs companies offered in our report includes Hetero Healthcare Limited, Teva Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories, Mylan N.V., Aurisco Pharmaceutical, ScinoPharm Taiwan, Avalon Pharma Pvt Ltd, Qilu Pharmaceutical, Amneal Pharmaceuticals, Genex Pharma, and Janssen Global Services, LLC.